HologicHOLX 57 EBITDA Margin % is 31.20% as of Dec. 2025, which is 9% below its 10-year median of 34.37. GuruFocus rates HOLX with a GF Score™ of 57/100 and a GF Value™ of $82.05. The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Hologic ranks better than 85.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hologic's EBITDA for the
three
months ended in Dec. 2025 was $327 Mil. Hologic's Revenue for the
three
months ended in Dec. 2025 was $1,048 Mil. Therefore, Hologic's EBITDA margin for the quarter that ended in Dec. 2025 was 31.20%.
Hologic (NAS:HOLX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hologic EBITDA Margin % Related Terms
Hologic EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hologic's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOLX vs WST, COO, ALGN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Hologic's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hologic EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hologic's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hologic's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hologic (HOLX) has a EBITDA Margin % of 31.20% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hologic and its competitors. This is near median its historical median of 34.37. Over the past decade, Hologic's EBITDA Margin % has ranged from 6.54 to 59.92. According to the industry distribution chart, Hologic ranks #117 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 14.3%.
Is Hologic's EBITDA Margin % too high?
Hologic's current EBITDA Margin % of 31.20% is near median its 10-year median of 34.37. Over the past 10 years, this metric has ranged from a low of 6.54 to a high of 59.92. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Hologic's value of 31.20% is 317.4% above this industry median. Based on the distribution chart, Hologic ranks #117 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's EBITDA Margin % compare to WST and COO?
According to the Medical Devices & Instruments industry distribution chart, Hologic ranks #117 out of 816 companies for EBITDA Margin %. This places Hologic in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Hologic's value of 31.20% is 317.4% above this benchmark. Historically, Hologic's own EBITDA Margin % has ranged from 6.54 to 59.92 over the past decade. While the company's 10-year median is 34.37 vs. the industry median of 7.48, Hologic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hologic's current EBITDA Margin % of 31.20% is 317.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hologic and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hologic's current EBITDA Margin % is 31.20%, which is near median its own 10-year median of 34.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (HOLX) has a current EBITDA Margin % of 31.20%. The stock's GF Value™ is $82.05, compared to a current price of $76.01 — trading 7.4% below its estimated fair value. The current EBITDA Margin % is 31.20%, which is near median its 10-year median of 34.37 and 317.4% above the Medical Devices & Instruments industry median of 7.48. Hologic's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hologic (HOLX), the current EBITDA Margin % is 31.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hologic (HOLX) Overvalued in 2026?
Based on GuruFocus' analysis, Hologic stock appears to be undervalued.
The current stock price of $76.01 is trading 7.4% below its estimated GF Value™ of $82.05.
Key valuation signals for HOLX:
EBITDA Margin %: 31.20% (near median its 10-year median of 34.37)
GF Value™: $82.05 vs. price of $76.01 (7.4% below fair value)
Industry Position: 317.4% above the Medical Devices & Instruments median (#117 of 816)
No single metric tells the full story. See the HOLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score
Get the complete analysis for HOLX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOLX has been successfully added to your 
